Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetic Interaction of BILR 355 and Truvada
NCT02253901Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2005
- Primary completion
- May 2005
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of BILR 355 in human immunodeficiency virus type 1 infection (HIV-1) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Area under the concentration-time curve from 0 to 24 hours at steady state of the analyte in plasma. Started Mar 2005; status: completed.
02
Drugs
BILR 355
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT02253901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02253901.